Unicycive Therapeutics, INC

Unicycive Therapeutics, Inc. announced a preliminary cash balance of approximately $61.4 million as of June 30, 2026, in its latest Form 8-K filing.

Unicycive Therapeutics has amended its sales agreement with Guggenheim Securities to increase its at-the-market offering capacity by $50 million.

Unicycive Therapeutics reports Q1 2026 financial results, with its oxylanthanum carbonate NDA resubmission on track for a June 29, 2026 PDUFA date.

Unicycive Therapeutics, Inc. announced the resignation of director Gaurav Aggarwal from its Board of Directors effective April 6, 2026.

Unicycive narrowed its 2025 net loss, reported $54.9M in cash and securities as of March 30, 2026, and confirmed a June 29, 2026 FDA PDUFA date for OLC with potential 3Q26 launch.

Unicycive Therapeutics, Inc. amended its sales agreement to double its at-the-market equity offering capacity to $100 million.

Unicycive Therapeutics reported a wider net loss for Q1 2026, driven by increased general and administrative expenses, despite a decrease in R&D spending.

Unicycive Therapeutics reported a reduced net loss and increased cash reserves in Q3 2025, while planning to resubmit its Oxylanthanum Carbonate NDA by year-end following an FDA meeting.

Unicycive Therapeutics, an early-stage biotech, reported a net loss for Q2 2025 and increased cash burn from operations, despite a recent $12.2 million equity raise and progress in its drug development pipeline.

Unicycive Therapeutics reports a net income of $0.6 million for Q1 2025, primarily driven by changes in the fair value of warrant liabilities, while expressing concerns about its ability to continue as a going concern.

Unicycive Therapeutics reports a net loss of $4.1 million for the third quarter of 2024, alongside updates on their drug development programs and recent financing activities.

Unicycive Therapeutics has amended its manufacturing agreement with Shilpa Medicare and reported its financial results for the second quarter of 2024, showing a significant increase in cash and a net loss.

Unicycive’s 10-K details a manufacturing-related FDA delay for oxylanthanum carbonate, a resubmitted NDA with a June 29, 2026 PDUFA, strengthened cash via ATM offerings, and new shareholder litigation.

Unicycive Therapeutics files its 10-K, detailing its financial results for 2024 and providing updates on its key drug development programs, including Oxylanthanum Carbonate (OLC) and UNI-494.

Unicycive Therapeutics' 2023 annual report details financial losses alongside advancements in clinical trials for their kidney disease treatments, Oxylanthanum Carbonate and UNI 494.

Sara Kenkare-Mitra, a Director of Unicycive Therapeutics, Inc., received 47,941 shares of common stock on May 14, 2026.

Sandeep Laumas, a Director of Unicycive Therapeutics, Inc., received 47,941 shares of common stock on May 14, 2026.

Unicycive Therapeutics CEO Shalabh Gupta was granted 762,200 restricted stock units as part of a compensation package.

Director Sara Kenkare-Mitra was granted 126,300 restricted stock units in Unicycive Therapeutics, Inc.

Director Sandeep Laumas was granted 126,300 restricted stock units in Unicycive Therapeutics, Inc. as part of an equity compensation package.

Pramod Gupta, EVP of Pharmaceuticals and BD at Unicycive Therapeutics, was granted 169,500 restricted stock units.

Unicycive Therapeutics announces its 2026 Annual Meeting of Stockholders, scheduled for June 19, 2026, to elect directors and ratify auditor appointment.

Unicycive Therapeutics, Inc. announced that its stockholders approved all proposals at the Annual Meeting held on June 9, 2025, including the election of four directors, ratification of its independent accounting firm, and a reverse stock split.

Unicycive Therapeutics files a second amendment to its proxy statement, updating the beneficial ownership table in advance of its annual meeting on June 9, 2025.

Unicycive Therapeutics announced a change in the time of its 2025 Annual Meeting of Stockholders, while the date and location remain the same.

Unicycive Therapeutics amends its proxy statement to clarify the voting rights of Series A and B Preferred Stock and the quorum requirements for its upcoming annual meeting on June 9, 2025.

Unicycive Therapeutics is holding its annual meeting on June 9, 2025, seeking stockholder approval for key proposals including a reverse stock split to maintain its Nasdaq listing and the election of directors.

BlackRock, Inc. has filed a Schedule 13G, reporting beneficial ownership of 5.3% of Unicivive Therapeutics Inc. common stock as of June 30, 2026.

Several entities affiliated with Millennium Management have reported a combined beneficial ownership of 1.8% of Unicycive Therapeutics' common stock as of June 30, 2026.

RA Capital Management and its affiliates filed an amended Schedule 13G disclosing a 9.9% beneficial ownership stake in Unicycive Therapeutics, Inc. as of March 31, 2026.

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, reported a 9.99% beneficial ownership stake in UNICYCIVE THERAPEUTICS, INC. as of December 31, 2025.

Octagon Capital Advisors LP and affiliated funds, along with Ting Jia, reported a combined 4.7% passive ownership stake in Unicycive Therapeutics, Inc. as of December 31, 2025.

Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have jointly reported beneficial ownership of 5.5% of Unicycive Therapeutics, Inc.'s common stock.